View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 4, 2020

Hydroxycloroquine found to offer no protection following Covid-19 exposure

By Allie Nawrat

In a study of more than 800 asymptomatic patients in the US and Canada, researchers at the University of Minnesota found that hydroxychloroquine did not protect them better from Covid-19 than placebo after 4 days of either high and moderate risk of exposure.

Health care workers accounted for 66.4% of the participants in this study, with 62.8% of them being physicians and 23.5% nurses.

The study, which was published in the New England Journal of Medicine, found that 107 of the 821 participants developed Covid-19 in the 14 of follow-up; this was split evenly between the hydroxychloroquine and placebo groups.

“This randomized trial did not demonstrate a significant benefit of hydroxychloroquine as postexposure prophylaxis for Covid-19,” the researchers concluded. “Whether preexposure prophylaxis would be effective in high-risk populations is a separate question, with trials ongoing.”

Last week, the UK’s healthcare regulator paused the University of Oxford’s international CopCov study of hydroxychloroquine and chloroquine to prevent Covid-19 in healthcare workers. This was linked to concerns about the efficacy and safety of the drug based on results of studies in the Lancet.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology